Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Dario GiuglianoMiriam LongoLorenzo ScappaticcioPaola CarusoKatherine EspositoPublished in: Cardiovascular diabetology (2021)
Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i.
Keyphrases
- cardiovascular events
- heart failure
- risk factors
- cardiovascular disease
- atrial fibrillation
- coronary artery disease
- type diabetes
- left ventricular
- emergency department
- mental health
- combination therapy
- glycemic control
- blood pressure
- risk assessment
- metabolic syndrome
- climate change
- replacement therapy
- health information
- acute heart failure